Arbutus Biopharma Financials - Benzinga

Arbutus Biopharma Corp

ABUSNASDAQ

Trade with Public

Trade with Public

$4.85

-0.03-0.61%

가까이에: Sep 25, 5:00 PM EST

$4.86

0.01010.21%

시간외: 7:57 PM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Arbutus Biopharma Financials

Arbutus Biopharma (ABUS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Arbutus Biopharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.014M Beat $700.000K Estimate

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 400 percent decrease over earnings of $0.01 per share from

Benzinga Newsdesk

PRO
Arbutus Biopharma Q1 EPS $0.87 Beats $(0.04) Estimate, Sales $179.126M Beat $750.000K Estimate

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $(0.04) by 2275 percent. This is a 769.23 percent increase over losses of $(0.13) per share from

Benzinga Newsdesk

PRO
Arbutus Biopharma Q4 EPS $(0.01) Beats $(0.03) Estimate, Sales $1.051M Miss $1.233M Estimate

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 85.71 percent increase over losses of $(0.07) per share from

Benzinga Newsdesk

PRO
Arbutus Biopharma Q3 EPS $(0.04) Misses $(0.03) Estimate, Sales $529.000K Miss $1.267M Estimate

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 60 percent increase over losses of $(0.10) per share from

Benzinga Newsdesk

PRO
Arbutus Biopharma Q2 EPS $0.01 Beats $(0.05) Estimate, Sales $10.74M Beat $1.59M Estimate

Benzinga Newsdesk

PRO
Arbutus Biopharma Q1 EPS $(0.13) Misses $(0.10) Estimate, Sales $1.76M Miss $1.78M Estimate

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 30 percent. This is a 30 percent decrease over losses of $(0.10) per share from the

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved